Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In this review, we highlight the past and present progress in our understanding and development of treatments based on GLP-1/glucagon co-agonism
Pichard, C., Roulet, M., Schutz, Y., Rossle, C., Chiolero, R., Temler, E., Schindler, C., Zurlo, F., Furst, P., and Jequier, E
Feb 2004;15(2):64-79
GLP-1 is contraindicated in patients including but not limited to: those with a personal or family history of medullary thyroid cancer, patients with multiple endocrine neoplasia type 2, patients with a hypersensitivity reaction to GLP-1 or any of the product components, as well as patients with pancreatitis, kidney disease, diabetic retinopathy or gallbladder disease
Structure-Activity Relationship (SAR) Studies The compound is utilized in structure-activity relationship research to investigate how sequence modifications affect receptor interaction, binding efficiency, and signaling pathway engagement
US$ 27.36
US$ 24.88
US$ 22.88
US$ 28.84
US$ 20.42
US$ 23.70
US$ 28.21
